Our results showed that the median OS time was 46.5 (95% CI: 39.7–53.3) months for HCC patients with low expression of LASS2 and 58.4 (95% CI: 51.9–64.9) months for HCC patients with high expression of LASS2 (p =  0.0019, Fig. 2A). The gene discussed is CERS2; the disease is hepatocellular carcinoma.